Skip to main content
main-content

Free registration

Medicine Matters is developed for healthcare professionals as

a premier resource for the latest clinical information in medicine.

Editors' pick

07-16-2018 | Quality of life | Editorial | Article

Tackling clinical inertia: The role of patient engagement

Carmen Soto and David Strain provide their insights on clinical inertia in diabetes care and present the co-production model of open communication as an innovative means to address this widespread clinical issue.

06-27-2018 | Sodium-glucose cotransporter-2 inhibitors | ADA 2018 | Video

Expert commentary: SGLT2 inhibition in type 1 diabetes patients

John Wilding has been sitting on the fence about the prospects for SGLT2 inhibitors in type 1 diabetes. Is he swayed by the latest findings? (3:43)

07-04-2018 | Metformin | Highlight | News

First trimester metformin exposure unlikely to raise congenital anomaly risk

A European-wide case–control study finds little evidence for risk to the developing fetus if a mother is taking metformin.

Latest from across the site

06-23-2018 | Cardiovascular outcomes | Review | Article

Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists

Scheen AJ. Diabetes Res Clin Prac 2018; 143: 88–100. doi: 10.1016/j.diabres.2018.06.008

06-23-2018 | Diabetes prevention | Review | Article

2020 vision: An overview of prospects for diabetes management and prevention in the next decade

Wang CY, Neil DL, Home P. Diabetes Res Clin Prac 2018; 143: 101–112. doi: 10.1016/j.diabres.2018.06.007

06-23-2018 | Medication adherence | Article

Cost-related medication non-adherence among US adults with diabetes

Kang H et al. Diabetes Res Clin Prac 2018. doi: 10.1016/j.diabres.2018.06.016

07-17-2018 | Primary care | News

HbA1c valid marker of blood glucose in anemia or CKD

The presence of mild-to-moderate anemia or chronic kidney disease does not have a clinically significant effect on the interpretation of glycated hemoglobin as a marker of glycemic control, Danish research shows.

Source:

Diabet Med 2018; doi: 10.1111/dme.13776

07-16-2018 | Sodium-glucose cotransporter-2 inhibitors | News

No significant increase in amputation risk with SGLT2 inhibitors in real-world study

Patients with type 2 diabetes who are treated with sodium-glucose cotransporter 2 inhibitors have numerically higher rates of amputation than those given dipeptidyl peptidase-4 inhibitors, but the difference does not reach statistical significance, researchers report.

Source:

Diabetes Obes Metab 2018; doi:10.1111/dom.13459

06-23-2018 | Type 1 diabetes | Review | Article

Closing the loop on managing youth with type 1 diabetes: Children are not just small adults

Sherr JL. Diabetes Care 2018. doi: 10.2337/dci18-0003

Meet our Editorial Board

Lori BerardSanjay KalraJay ShubrookProfessor John Wilding

New Content Item Meet our Advisory Board

image credits